QuidelOrtho Eyes $1.5B Sale of Its Testing Unit
QuidelOrtho is reportedly planning to offload its testing division for $1.5 billion, per the Financial Times.
QuidelOrtho is moving to shed a major piece of its business. The diagnostics company is reportedly in talks to sell its testing unit for $1.5 billion, according to the Financial Times. That's a notable chunk of change for a company that's been navigating a post-pandemic hangover in demand for COVID-related testing products.
This kind of asset sale signals management is serious about slimming down and refocusing. When a company carves out a division at a price tag like $1.5 billion, it's usually a play to pay down debt, return capital, or double down on higher-margin core operations. Watch for any follow-on announcements about what QuidelOrtho plans to do with the proceeds.
Read more US Strikes Iran Again After Tanker Hit in Strait of Hormuz →
For traders, the question is simple: does the market think $1.5 billion is a fair price? If the unit is being sold at a discount, that's a red flag about underlying demand. If it clears at or above expectations, expect the stock to get a lift. Either way, a deal of this size moves the needle and deserves your attention before the close.
Diagnostics names have been a tough trade since COVID test demand cratered. A strategic divestiture could be exactly the catalyst QDEL needs to re-rate higher — or it could confirm that the business is smaller than the bulls hoped. Stay nimble and watch the tape when this deal gets closer to official confirmation.
Continue reading at SeekingAlpha.
